(18)F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

Response rates of unselected non–small cell lung cancer (NSCLC) patients to the epidermal growth factor receptor inhibitor erlotinib are low and range from 10% to 20%. Early response assessments are needed to avoid costs and side effects of inefficient treatments. Here we determined whether early ch...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Nucl Med
Main Authors: Benz, Matthias R., Herrmann, Ken, Walter, Franziska, Garon, Edward B., Reckamp, Karen L., Figlin, Robert, Phelps, Michael E., Weber, Wolfgang A., Czernin, Johannes, Allen-Auerbach, Martin S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5021512/
https://ncbi.nlm.nih.gov/pubmed/22045706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.111.095257
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados